91桃色

Pediatric cancer; Precision medicine; Treatment toxicity; Pharmacogenomics; Targeted therapy; immunotherapy

Introduction

Pediatric cancer treatment has evolved significantly over the past few decades, leading to improved survival rates for many childhood malignancies [1]. However, conventional therapies, including chemotherapy and radiation, often come with substantial toxicity that can result in both acute and long-term adverse effects. These toxicities not only impact immediate treatment outcomes but also contribute to lifelong complications such as organ dysfunction, neurocognitive deficits, and secondary malignancies. As a result, there is a growing emphasis on minimizing toxicity without compromising therapeutic efficacy [2].

Precision medicine has emerged as a transformative approach in pediatric oncology, offering personalized treatment strategies that optimize efficacy while reducing toxicity. By integrating genomic profiling, pharmacogenomics, and biomarker-driven treatment selection, precision medicine enables tailored interventions that account for individual variability in drug metabolism, response, and susceptibility to adverse effects. In addition, advancements in immunotherapy and targeted therapies have provided new opportunities to mitigate toxicity by selectively attacking cancer cells while sparing healthy tissues [3].

This paper explores the role of precision medicine in minimizing treatment-related toxicity in pediatric cancer therapy. It highlights key strategies, including the use of genetic and molecular profiling, adaptive dosing techniques, and novel targeted agents designed to reduce collateral damage. Additionally, the integration of supportive care measures and emerging technologies in toxicity prediction and prevention will be discussed, offering insights into the future direction of pediatric oncology [4].

Discussion

The integration of precision medicine in pediatric cancer therapy has shown significant promise in minimizing treatment-related toxicity while maintaining therapeutic efficacy. Traditional chemotherapy and radiation approaches, while effective, are often associated with severe short-term and long-term toxicities, including myelosuppression, organ damage, neurocognitive impairment, and secondary malignancies. The emergence of precision medicine strategies aims to address these challenges by tailoring treatment to the individual patient’s genetic, molecular, and pharmacokinetic profile. One of the most impactful applications of precision medicine is the use of pharmacogenomics to guide drug selection and dosing [5]. By analyzing genetic variations that influence drug metabolism and toxicity, clinicians can optimize chemotherapy dosing to reduce adverse effects while maintaining therapeutic efficacy. For example, variations in TPMT and NUDT15 genes have been linked to heightened sensitivity to thiopurines, allowing dose adjustments to prevent severe hematologic toxicity in pediatric leukemia patients. Similarly, CYP2D6 and DPYD polymorphisms influence the metabolism of drugs like tamoxifen and fluoropyrimidines, respectively, necessitating personalized dosing strategies [6].

Beyond pharmacogenomics, biomarker-driven therapies have significantly improved treatment specificity, reducing off-target toxicity. Targeted agents such as tyrosine kinase inhibitors (e.g., imatinib for Philadelphia chromosome-positive leukemia) and monoclonal antibodies (e.g., dinutuximab for neuroblastoma) offer tumor-specific activity, minimizing damage to healthy tissues. Immunotherapies, including CAR-T cell therapy, have revolutionized treatment for relapsed/refractory leukemia, providing durable responses with reduced long-term toxicity compared to conventional chemotherapy [7]. However, immune-related adverse effects, such as cytokine release syndrome (CRS) and neurotoxicity, remain challenges requiring further refinement. Another essential component of toxicity mitigation is supportive care innovations. Advances in protective agents, such as dexrazoxane for anthracycline-induced cardiotoxicity and mesna for ifosfamide-induced hemorrhagic cystitis, have helped reduce specific toxicities. Additionally, the use of real-time therapeutic drug monitoring and machine learning-based predictive models enables early identification of toxicity risks, allowing proactive intervention [8].

Despite these advancements, challenges remain in fully implementing precision medicine across pediatric oncology. The heterogeneity of pediatric cancers, limited availability of targeted agents for specific malignancies, and the high cost of genomic testing pose barriers to widespread adoption. Moreover, ethical considerations, such as genetic testing in children and data privacy concerns, must be carefully addressed to ensure responsible integration of precision medicine into clinical practice [9]. Moving forward, ongoing research in multi-omics integration, artificial intelligence-driven predictive modeling, and next-generation targeted therapies will further refine toxicity reduction strategies. Collaboration among oncologists, geneticists, and data scientists will be crucial in expanding the accessibility and effectiveness of precision medicine approaches. Ultimately, minimizing toxicity through precision medicine not only improves immediate treatment outcomes but also enhances the long-term quality of life for pediatric cancer survivors [10].

Conclusion

Minimizing toxicity in pediatric cancer therapy remains a critical challenge, as conventional treatment approaches often lead to significant short-term and long-term adverse effects. Precision medicine has emerged as a transformative strategy, enabling clinicians to tailor therapies based on genetic, molecular, and pharmacokinetic profiles. Through the integration of pharmacogenomics, biomarker-driven targeted therapies, and personalized dosing strategies, precision medicine has significantly reduced the toxic burden associated with traditional chemotherapy and radiation. Advancements in immunotherapy and supportive care innovations have further contributed to improving treatment tolerability and long-term outcomes for pediatric patients. However, challenges such as the heterogeneity of pediatric cancers, accessibility to genomic testing, and the high cost of targeted therapies must be addressed to ensure broader implementation. Continued research, multidisciplinary collaboration, and technological advancements in predictive modeling and multi-omics integration will be essential in refining precision medicine approaches. By prioritizing toxicity reduction while maintaining treatment efficacy, precision medicine not only enhances survival rates but also improves the quality of life for pediatric cancer survivors. The future of pediatric oncology lies in the continued evolution of personalized treatment strategies that minimize harm, optimize therapeutic outcomes, and pave the way for safer, more effective cancer therapies.

References

1. Olsen LF, Issinger OG, Guerra B (2013) . Redox Rep 18: 245-252.

, ,

2. Pernas L, Scorrano L (2016) . Annu Rev Physiol 78: 505-531.

, ,

3. Alston CL, Rocha MC, Lax NZ, Turnbull DM, Taylor RW, et al (2017) . J Pathol 241: 236-250.

, ,

4. Ong SB, Kalkhoran SB, Hernandez-Resendiz S, Samangouei P, Ong SG, et al. (2017) . Cardiovasc Drugs Ther 31: 87-107.

, ,

5. Yu T, Robotham JL, Yoon Y (2006) . Proc Natl Acad Sci U S A 103: 2653-2658.

, ,

6. Jheng HF, Tsai PJ, Guo SM, Kuo LH, Chang CS, et al. (2012) . Mol Cell Biol 32: 309-319.

, ,

7. Tailor D, Hahm ER, Kale RK, Singh SV, Singh RP (2014) . Mitochondrion 16: 55-64.

, ,

8. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z, Group AHEW, et al. (2003) . Clin Nutr 22: 321-336.

, ,

9. Marcadenti A, Mendes LL, Rabito EI, Fink JDS, Silva FM, et al. (2018) . J Parenter Enter Nutr 42: 1168-1176.

, ,

10. Arslan M, Soylu M, Kaner G, İnanç N, Başmısırlı E, et al. (2016) . Hippokratia 20: 147-152.

,